Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints Elliott Sigal to Board

Bristol-Myers Squibb has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee

Bristol-Myers Squibb (BMS) has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee.

Sigal joined BMS in 1997 as vice president of applied genomics. He has since served in critical leadership roles within R&D, including drug discovery and development. During Sigal's time as chief scientific officer, BMS achieved eight new drug approvals and filled the drug pipeline with numerous mid- and late-stage assets, five of which could be approved by 2012. 

"We are very excited to have Elliott join our Board," said James M Cornelius, chairman, Bristol-Myers Squibb. "Under his leadership, our R&D organisation has become one of the most productive in the industry. Today's appointment recognises his great contribution to the company." 
Sigal has held the role of executive vice president, chief scientific officer and president, BMS research and development since 2004. He reports to Lamberto Andreotti, CEO, BMS.

2nd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics